|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2004-8-27
|
|
pubmed:abstractText |
Most studies establishing the role of antiviral therapy in patients with chronic hepatitis C (CHC) excluded the patients with normal ALT levels. Small trials with interferon monotherapy suggested a limited efficacy and/or de novo ALT elevations. We sought to evaluate the efficacy of two doses of interferon alfa-2b (IFN) with ribavirin (RBV) in patients with normal ALT [correction].
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0002-9270
|
|
pubmed:author |
pubmed-author:AhmedFurqaanF,
pubmed-author:AntignanoLouisL,
pubmed-author:BachNancyN,
pubmed-author:BrownRobert SRSJr,
pubmed-author:DieterichDouglas TDT,
pubmed-author:EspositoStephen PSP,
pubmed-author:GabbaizadehDavidD,
pubmed-author:GedersJaneJ,
pubmed-author:JacobsonIra MIM,
pubmed-author:KlionFranklinF,
pubmed-author:LebovicsEdwardE,
pubmed-author:LevendogluHulyaH,
pubmed-author:RussoMark WMW,
pubmed-author:TobiasHillelH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
99
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1700-5
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15330905-Administration, Oral,
pubmed-meshheading:15330905-Adult,
pubmed-meshheading:15330905-Alanine Transaminase,
pubmed-meshheading:15330905-Biopsy, Needle,
pubmed-meshheading:15330905-Confidence Intervals,
pubmed-meshheading:15330905-Dose-Response Relationship, Drug,
pubmed-meshheading:15330905-Drug Administration Schedule,
pubmed-meshheading:15330905-Drug Therapy, Combination,
pubmed-meshheading:15330905-Female,
pubmed-meshheading:15330905-Follow-Up Studies,
pubmed-meshheading:15330905-Hepatitis C, Chronic,
pubmed-meshheading:15330905-Humans,
pubmed-meshheading:15330905-Injections, Subcutaneous,
pubmed-meshheading:15330905-Interferon-alpha,
pubmed-meshheading:15330905-Liver Function Tests,
pubmed-meshheading:15330905-Male,
pubmed-meshheading:15330905-Middle Aged,
pubmed-meshheading:15330905-Probability,
pubmed-meshheading:15330905-Recombinant Proteins,
pubmed-meshheading:15330905-Reference Values,
pubmed-meshheading:15330905-Ribavirin,
pubmed-meshheading:15330905-Risk Assessment,
pubmed-meshheading:15330905-Severity of Illness Index,
pubmed-meshheading:15330905-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.
|
|
pubmed:affiliation |
Department of Gastroenterology and Hepatology, Weill Medical School of Cornell University, 450 East 69th Street, New York, NY 10021, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
